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https://doi.org/10.1016/j.celrep.2020.108352SUMMARYSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is constantly evolving. Prior studies focused
on high-case-density locations, such as the northern and western metropolitan areas of the United States.
This study demonstrates continued SARS-CoV-2 evolution in a suburban southern region of the United
States by high-density amplicon sequencing of symptomatic cases. 57% of strains carry the spike D614G
variant, which is associated with higher genome copy numbers, and its prevalence expands with time.
Four strains carry a deletion in a predicted stem loop of the 30 UTR. The data are consistent with community
spreadwithin local populations and the larger continental United States. The data instill confidence in current
testing sensitivity and validate ‘‘testing by sequencing’’ as an option to uncover cases, particularly nonstan-
dard coronavirus disease 2019 (COVID-19) clinical presentations. This study contributes to the understand-
ing of COVID-19 through an extensive set of genomes from a non-urban setting and informs vaccine design
by defining D614G as a dominant and emergent SARS-CoV-2 isolate in the United States.INTRODUCTION
The coronavirus disease 2019 (COVID-19) pandemic is an urgent
public health emergency, with over 200,000 deaths in the United
States alone. COVID-19 is caused by infection with severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2). Typical
symptoms for COVID-19 include fever, cough, shortness of
breath, fatigue, myalgias, headache, sore throat, abdominal
pain, and diarrhea (Wu et al., 2020; Zhou et al., 2020a, 2020b).
Patients admitted to the hospital generally have pneumonia
and abnormal chest imaging (Bhatraju et al., 2020; Chen et al.,
2020). COVID-19 is also associated with other complications,
including acute respiratory failure and acute respiratory distress
syndrome, which appear to be significant predictors of mortality.
Severe COVID-19 is disproportionately observed in the elderlyC
This is an open access article undand individuals with underlying comorbidities. COVID-19 has
not similarly impacted children (Guan et al., 2020; CDC
COVID-19 Response Team, 2020; Verdoni et al., 2020; Xu
et al., 2020b); however, other SARS-CoV-2 disease manifesta-
tions, such as Kawasaki disease, are emerging in this group.
The first reported SARS-CoV-2 clusters appeared in the Wu-
han province in China and have since rapidly spread across
the world (Li et al., 2020a; Wu et al., 2020; Zhu et al., 2020).
The primary means of transmission is by oral secretions, though
viral RNA has also been detected in blood, stool, and semen (Kim
et al., 2020; Zou et al., 2020). Social distancing, rapid case ascer-
tainment, physical barriers, and quarantine of infected persons
have proven successful in limiting the impact of COVID-19. For
these public health measures to remain effective and sustain-
able, it is important to understand the pathways of transmissionell Reports 33, 108352, November 3, 2020 ª 2020 The Author(s). 1
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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OPEN ACCESSthrough aggressive contact tracing and virus testing. Of high
concern with regards to SARS-Cov-2 is that the virus may be
shed prior to the onset of clinical symptoms, at late times after
the cessation of clinical symptoms, and by asymptomatically in-
fected persons (Arons et al., 2020; He et al., 2020; Hijnen et al.,
2020; van Doremalen et al., 2020; Wölfel et al., 2020; Xu et al.,
2020a).While antibody testing identifies patients with prior expo-
sure (Long et al., 2020), only targeted nucleic acid amplification
testing (NAT) or SARS-CoV-2 antigen detection can identify
actively transmitting individuals.
The SARS-CoV-2 genome shares 79.6% sequence identity
with SARS-CoV, the causative agent of SARS in 2002. It shares
96% sequence identity with a bat coronavirus (BatCoV), RaTG13
(GenBank: MN996532) (Ceraolo and Giorgi, 2020; Lu et al.,
2020b; Zhou et al., 2020b). SARS-CoV entry is determined by
the spike protein ORFS (Wan et al., 2020). ORF S hasmany inter-
action surfaces and is the target of neutralizing antibodies. The S
protein uses human ACE2 (hACE2) as a receptor and is proteo-
lytically activated by human proteases (Hoffmann et al., 2020;
Shang et al., 2020). Comparative analysis shows that between
SARS-CoV-2 and either SARS-CoV or bat-derived SARS-like
coronavirus (bat SARS-CoV) (Andersen et al., 2020; Wu et al.,
2020), the sequence identities are the least alike for spike protein
gene (S). SARS-CoV-2 has a longer spike protein as compared
to bat SARS-CoV, human SARS-CoV, and middle east respira-
tory syndrome coronavirus (MERS-CoV) (Lu et al., 2020b).
Although SARS-CoV-2 and SARS-CoV only share 79% identity
at the whole-genome scale, their spike protein receptor binding
site sequences aremore similar compared to bat SARS-CoV and
MERS-CoV (Lu et al., 2020b). Residues at the receptor-binding
site have evolved for better association with ACE2 compared
to SARS-CoV (Wan et al., 2020; Wrapp et al., 2020) and can be
attributed to thesemolecular features; five of the residues critical
for binding to ACE2 are different in SARS-CoV-2 as compared to
SARS-CoV (Wan et al., 2020; Wrapp et al., 2020), and a func-
tional polybasic cleavage site (RRAR) is present at the S1/S2
boundary of the SARS-CoV-2 spike protein (Andersen et al.,
2020; Walls et al., 2020). The polybasic cleavage site allows for
effective cleavage by furin and other proteases, which is impor-
tant for viral infectivity (Letko et al., 2020). The additional proline
may also result in O-linked glycans to S673, T678, and S686 that
can be important in shielding key epitopes or residues (Andersen
et al., 2020). Ascertaining whether these key residues remain
invariable as the pandemic progresses or evolve over time is
crucial to ensure testing accuracy and rational vaccine design.
Phylogenetic analysis translates viral genome sequences into
a hierarchical classification based on sequence similarity. Early
analyses established SARS-CoV-2 as a Sarbecovirus, in the
same clade as BatCoVs, substantiating its use as an outgroup
here (Jaimes et al., 2020). Initial analyses of human SARS-
CoV-2 genomes established threemajor variant types worldwide
(Forster et al., 2020). Clade B was derived from clade A by a syn-
onymous T8782C mutation in ORF1ab and a nonsynonymous
C28144T mutation that changes a leucine to serine in ORF8 (Ce-
raolo and Giorgi, 2020; Forster et al., 2020). Clade C was derived
from clade B by a nonsynonymous G26144T mutation that
changes a glycine to valine in ORF3a. A and C types are mainly
found in Europe and the United States. B type is mainly found in2 Cell Reports 33, 108352, November 3, 2020East Asia. Other analyses arrived at different clades and, unfor-
tunately, different naming conventions (Yang et al., 2020; Zhang
et al., 2020). Additional clades have since been recognized,
including clade G, which is defined by a nonsynonymous sin-
gle-nucleotide variant (SNV) in spike protein at amino acid posi-
tion 614. Multiple studies continue to study SARS-CoV-2
sequence evolution based on an ever-increasing set of se-
quences collected at GISAID (GISAID, 2020; Shu andMcCauley,
2017), GenBank, and Nextstrain (Hadfield et al., 2018). The
phylogenetic analysis of SARS-CoV-2 is very much in flux. Ana-
lyses represent a snapshot of the time of prepublication. The
clade designations used here were derived from GISAID at the
time of data analysis.
To provide finer granularity about biological changes during
SARS-CoV-2 transmission, we employed next-generation
sequencing (NGS) as an independent screening modality. This
allowed us to reconstruct the mutational landscape of cases
seen at a tertiary clinical care center in the southeastern United
States from the start of the North Carolina (NC) epidemic on
March 3, 2020, until past the peak of the first major wave of infec-
tions. The samples cover the period when community spread in
NC was established and when the state-wide stay-at-home or-
der was issued (March 30 to May 8, 2020).
SARS-CoV-2 testing remains limited in many countries due to
a shortage of personal protective equipment, testing kits, and
diagnostic capacity. The Centers for Disease Control (CDC)
guidelines during the time of sampling prioritized patients with
specific clinical symptoms (fever, cough, and shortness of
breath) and curtailed testing to only a subset of all probable
cases. Individuals not fitting the clinical criteria for testing, as
well as asymptomatic individuals, were excluded. To evaluate
if any cases were missed because of this triage algorithm, naso-
pharyngeal (NP) swabs for three groups of patients were evalu-
ated (n = 175 known SARS-CoV-2-positive NP samples, n = 41
known SARS-CoV-2-negative NP samples, and n = 12 NP sam-
ples of unknown status [i.e., the patient had symptoms justifying
sample collection but was not prioritized for clinical SARS-CoV-2
testing]). ‘‘Testing by sequencing’’ was negative for all negative
samples, less sensitive for weakly positive samples, and uncov-
ered five new cases among previously not tested cases. The in-
dex case in NC was linked to the US outbreak in the state of
Washington. Phylogenetic analyses established the dominance
of the S protein D614G SNV among this population, which has
been increasing over time through community spread and was
introduced initially by a person returning from Europe.
RESULTS
Whole-Genome SARS-CoV-2 Sequencing through High-
Density Amplicons
The University of North Carolina at Chapel Hill Medical Center
(UNCMC) used one of two NATs to test for the presence of
SARS-CoV-2 RNA, one laboratory-developed test based on
the protocol by Corman et al. (2020) and the commercially avail-
able Abbott real-time SARS-CoV-2 assay, both under the EUA
provision of the US Food and Drug Administration. Both tests
report the presence or absence of SARS-CoV-2 RNA. Remnant
NP samples were subjected to targeted sequencing using the
Figure 1. Analysis of Sequencing Coverage
(A) Distribution of R103 coverage across all
samples. The percentage of samples is shown on
the vertical axis and log10 total mapped reads on
the horizontal axis. Color indicates known positive
(red), negative (blue), and unknown samples (gray).
(B) Relationship between mapped reads (on the
vertical axis) and relative viral load (N1) or total RNA
levels (on the horizontal axis).
(C) Quality of samples submitted to GenBank GI-
SAID. Percentage of genome covered is on the
vertical axis, and coverage level is on the horizontal
axis.
(D) Quality of additional samples used for SNV
analysis. Percentage of genome covered is on the
vertical axis, and coverage level is on the horizontal
axis.
(E) Relative coverage of aligned reads per position
of samples with median coverage >5,000 reads is
shown on the vertical axis for each position of
SARS-CoV-2, as shown on the horizontal axis. Red
line indicates a loess fit of the data (n = 28 samples).
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OPEN ACCESSThermo Fisher AmpliSeq SARS-CoV-2 assay and S5 Ion Torrent
sequencing platform. A subset of isolates was subjected to 30
and 50 rapid amplification of cDNA ends (RACE) followed by
Sanger sequencing to verify the sequences in the highly struc-
tured untranslated regions of the genome. Individual sequence
reads were mapped to the SARS-CoV-2 reference sequence
(NC_045512) and a strain-specific consensus sequence was
generated and SNV recorded. The finished genomes are submit-
ted to GenBank and GISAID and were named according to
convention (Coronaviridae Study Group of the International
Committee on Taxonomy of, 2020).
A total of n = 175 known positive samples and positive control
(full-length genomic RNA from strain SARS-CoV-2/human/USA-
WA1/2020; GenBank: MN985325) were subjected to NGS. The
number of mapped reads varied substantially across samples, re-
flecting the differences in the amount of virus per sample. The dis-




(see also Table S1). As expected, more
mapped reads yielded higher coverage.
Of the 33 negative controls, none had
>102 total reads aligned. Of the positive
samples, >5 3 103 total mapped reads
were needed to obtain 13 coverage of
the whole genome, and a minimum of
3.1 3 104 reads were needed to obtain
>90% coverage at 103. The number of
reads aligned varied depending on the viral
load, as determined by real-time qPCR us-
ing CDC primer N1, but not total RNA, as
determined using RNase P, of the samples
(Figure 1B). In this assay, any crossing
point (CP) <35 for SARS-CoV-2 qPCR
yielded reliable coverage, which increased
linearly with viral load. At a CP R35, most
positive samples still yielded reads that
mapped to the target genome and thus al-lowed detection of SARS-CoV-2 sequences; however, the results
were less consistent, and coverage was more variable. As ex-
pected, total RNA (measured by RNase P) was not associated
with sequencing coverage and varied considerably across sam
ples, even though each sample used the same amount of virus
transport medium (VTM).
The coverage level distribution is shown in Figures 1C and 1D
Figure 1C represents the subset of samples for which high-qual-
ity genomes were submitted to GenBank and GISAID. Figure 1D
represents samples, with more variable complete coverage
These samples were nevertheless included in SNV calling, as
the SNV algorithm relies on local coverage rather than overal
coverage. As a result, the variant calls represent a conservative
estimate of SNV distribution in this sample set. Figure 1E shows
the per nucleotide coverage for all genomes with median
coverage R5,0003. Median coverage of >5,0003 was required
to ensure >99% genome coverage without a single amplicon
(legend on next page)






OPEN ACCESSdropout. The nucleotide composition of SARS-CoV-2 was
largely balanced and did not contain repeats larger than
sequencing length. Hence, coverage was continuous across
the genome, except for the 50 and 30 UTRs. Targeted amplifica-
tion using this primer set missed the first 42 nt at the 50 end and
29 nt, starting at 29,843, at the 30 end of the viral genome. These
regions are conserved across most SARS-CoV-2 sequences in
GenBank, many of which are themselves incomplete or known
to suffer amplification bias (van Dorp et al., 2020). The limiting
factor was not sequencing depth per se; rather, samples of
low viral load failed in the targeted amplification step for individ-
ual amplicons. Samples with low viral load were re-sequenced.
A subset of positive samples (n = 33) were independently re-
sequenced and yielded 251 high-confidence SNVs. No new
SNVs were uncovered upon resequencing; 180 SNVs were
confirmed and 71 SNVs were lost upon pooling multiple
sequencing runs for the same sample due to the frequency drop-
ping below 90%. Of the 71 SNVs, 50 possessed a majority vote
matching the reference and 21 possessed a majority vote
matching the prior SNV call. Target capture efficiency was veri-
fied using multiple dilutions and compared to unbiased RNA
sequencing (RNA-seq) of the reference strain SARS-CoV-2/hu-
man/USA-WA1/2020 (Figure S1). Targeted sequencing
coverage was uniform over a 50-fold range of input RNA; it
was higher than RNA seq, except in the terminal regions that
were not covered by PCR amplicons. In some cases, as little
as 5 mL VTM from a single swab had sufficient virus to obtain a
full-length viral genome sequence at 1,0003. These data are
consistent with the astonishingly high reported genome copy
numbers of SARS-CoV-2 in some cases (Yu et al., 2020) and
demonstrate the principal suitability of testing by sequencing
as a diagnostic option for SARS-CoV-2 and other rapidly
evolving viruses.
The average quality score per read is set to a minimal average
phred score of 20 corresponding sequencing error rate of 1%
and to a false-positive probability of any individual base of
0.1% and a true-positive probability of 99.9%. Using a theoret-
ical model (Petrackova et al., 2019) based on the binomial distri-
bution, a minimal coverage of 103 was expected sufficient to
call SNVs with an allele frequency of R90%.
Twelve samples were collected during the same calendar
period from individuals presenting with respiratory complaints
but no indication for SARS-CoV-2 testing according to CDC
guidelines. 5 of 12 yielded >5% genome coverage (Figures
S2A–S2L). The remainder had reads aligned only to regions of
the genome that have low complexity; 2 out of 12 had a
sequence coverage distribution, at 57% and 34%, respectively,Figure 2. Phylogenetic Analysis
(A) Distribution of high-confidence SNVs across the genome. The genome positio
vertical axis. Clade-defining SNVs are indicated by GISAID designations.
(B) Neighbor-joining tree of whole SARS-CoV-2 genomes, including the first ca
participating in a cruise). The bat coronavirus genome strain RaTG13 was used a
major branches and the difference between SARS and SARS-CoV-2 (0.02).
(C) Neighbor-joining tree based on amino acids for S protein. Support values ar
samples are in blue, Washington State samples, including several independent
other US isolates in black, representative German isolates in gold, and represen
quences and protein sequences are from GISAID and GenBank.consistent with the presence of the target virus. Three other sam-
ples had coverage of 20%, 13%, and 10%. At the time of study,
SARS-CoV-2 testing guidelines were extremely restrictive due to
a lack of supplies. Patients with clear clinical symptoms of
COVID-19 were not tested but treated on the basis of clinical
diagnosis alone, and patients with respiratory symptoms not
exactly matching CDC/COVID-19 criteria were not tested either.
None of the samples in this study originated from asymptomatic
patients. Though the number of unknowns tested was small, the
results suggest that limiting testing to narrowly defined case
criteria misses a significant number of cases and thus transmis-
sion events.
Sequence Analysis Reveals the Presence of Two Clades
of SARS-CoV-2
Putting individual sequences into context is key to understand-
ing SARS-CoV-2 transmission. Sequencing identified n = 139
samples with at least one high-confidence SNV as compared
to the reference sequence. Of these, n = 79 (57%) carried the
S protein D614G SNV, a mutation implicated in higher pathoge-
nicity of the virus (Becerra-Flores and Cardozo, 2020). Samples
carrying the D614G SNV had higher SARS-CoV-2 genome loads
as measured by CDC N3-primer directed real-time qRT-PCR for
SARS-CoV-2 (p% 0.002 byWilcoxon signed rank test). A similar,
but not significant trend emerged using CDC N1-primer directed
real-time RT-qPCR for SARS-CoV-2, but not for total RNA levels
as measured by CDC RNase P- directed real-time RT-qPCR
(Figures S2M–S2O). Figure 2A shows the SNV distribution of
the data, color-coded by the week of collection. These data
include high-confidence SNVs of genomeswith <99%coverage,
whereas the phylogenetic reconstructions are only based on
complete genomes (R99% coverage) that were submitted to
GenBank (and also present in GISAID). This SNV distribution
was dominated by isolates representing clade A and some of
clade B, the dominant clades in North America and Europe (For-
ster et al., 2020). The NC stay-at-home order was enacted on
March 30, 2020, and the sample collection concluded on April
11, 2020 (i.e., covering a period of unrestrained local spread).
The SNV pattern is consistent with the idea that SARS-CoV-2
was introduced into NC by travelers from the continental United
States and that this population was in equilibrium with the gen-
eral population of the United States
Unlike retroviruses, such as human immunodeficiency virus
(HIV) or hepatitis C virus, CoVs do not exist as co-existing
sequence swarms within a person, since CoVs employ a proof-
reading RNA-dependent RNA polymerase (Agostini et al., 2018;
Graham et al., 2012). Rather, a single variant seems to dominatens (NC_045512) are on the horizontal axis, and the count of samples are on the
ses reported in NC (a person returning from Washington [WA] and a person
s an outlier to root the tree. Average nucleotide difference is shown for the two
e listed at the major branch points. The colors indicate geographic origin: NC
sequences for SARS-CoV-2/human/USA/WA1/2020 in green, representative
tative Chinese isolates, including NC_045512, in red. Additional genome se-
Cell Reports 33, 108352, November 3, 2020 5
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OPEN ACCESSthe transmission events. Consistent with the biology of CoV, this
study did not find widespread evidence of minor SNVs. Fig-
ure S1B shows the analysis of lower frequency variants (down
to 70% frequency). The majority of high-quality (phred score
R20) SNVs called were present at >90% frequency (n =
1,100). Including SNVs with a frequency of 80%–90% added
n = 61 additional variants (5.0%). Including SNVs with a fre-
quency of 70%–80% added an additional 40 variants (3.3%).
One limitation of all targeted sequencing efforts is the large num-
ber of PCR amplifications that are conducted to enrich for virus se-
quences prior to building the library. To explore the effect of ampli-
con-PCR-induced duplications on sequencing accuracy, we
repeated our analysis using only unique reads and obtained the
same high-prevalenceSNV.Amplicon duplications becameprom-
inent at read counts >104.5 (Figure S1B). As the SARS-CoV-2
genome is 3 3 104 and the median read length was 204 ± 29
(mean ± SD), this threshold corresponds to 200-fold median
coverage. This suggests that only deduplicate reads should be
used in amplicon sequencing and that requiring extraordinary
levelsof sequencecoveragemay introduceabiasof oversampling,
which is well recognized in the bacterial 18S sequencing field.
Independently derived consensus genomes from the SARS-
CoV-2/human/USA-WA1/2020 isolates showed evidence of
divergence between the original isolate, the seed stock, and
commercially distributed standard (Figure 2B). Similar culture-
associated changes were recently reported for a second, cul-
ture-amplified reference isolate, Hong Kong/VM20001061/
2020 (GenBank: MT547814). This is not surprising, given that
any large-scale virus amplification in culture is accompanied
by virus evolution, but it raises concerns about the utility of using
a natural isolate, rather than a molecular clone (Graham et al.,
2018; Thao et al., 2020), as the standard for sequencing.
The phylogeny based on whole-genome nucleotide sequences
revealed several interesting facets. Predictably, all UNC isolates of
SARS-CoV-2 were significantly different from SARS-CoV and
RaTG13 (Figure 2B, purple). RaTG13 was used as an outgroup
for clustering. The first NC case (NC_6999; Figure 2B, arrow
labeled ‘‘WA’’) was a person returning from Washington, and
sequence confirmed at the CDC (NC-CDC-6999). It initiated a
branch of cases related to the initial isolate SARS-CoV-2/hu-
man/CHN/Wuhan-01/2019 (NCBI Accession: NC_045512). The
branch of cases (Figure 2B, arrow labeled ‘‘cruise’’) contains the
majority of NC cases, several cases isolated in neighboring Vir-
ginia (Figure 2B, black cases), and a cluster of cases reported in
Germany (DEU, orange). It also contains several early cases, rep-
resenting the individual who participated in a cruise.
SARS-CoV entry is determined by the spike protein ORF S,
and S is the target of neutralizing antibodies. Figure 2C shows
the phylogenetic analysis of the S protein across all samples,
the index cases for NC deposited by the NC Department of
Health and Human Services, and representative examples
from the United States, China, and Germany. Two branches
emerged, one containing isolates from China, Washington, and
Germany and a second containing United States and German
sequences only. Since the S protein is shorter and more
conserved across SARS-CoV-2, the limited numbers of SNVs
did not support as detailed a lineage mapping as the whole-
genome nucleotide sequences.6 Cell Reports 33, 108352, November 3, 2020One large deletion was identified in four independent samples:
14 nt were deleted beginning at position 29745 (indicated in Fig-
ure 2C by a delta symbol). This region is within the previously
recognized ‘‘coronavirus 30 stem-loop II-like motif (s2m).’’ This
was confirmed in multiple isolates, supported by multiple, inde-
pendent junction-spanning reads (Figures 3A and 3B). Junctions
were mapped to single-nucleotide resolution directly from indi-
vidual reads. To confirm our deep-sequencing results, we per-
formed 30 UTR site-specific amplification and Sanger-based
sequencing (Figures 3E–3G). The variant 30 end does not destroy
overall folding but introduces a shorter stable hairpin (Figures 3C
and 3D). How this mutation affects viral fitness remains to be
established.
In sum, this study generated exhaustive SNV information rep-
resenting the introduction and spread of SARS-CoV-2 across a
suburban low-density area in the southern United States All sam-
ples were from symptomatic cases, and themajority of genomes
clustered with variants that predominate the outbreak in the
United States, rather than Europe or China. This supports the
notion that the majority of United States cases were generated
by domestic transmission.
DISCUSSION
This study demonstrates extensive shedding of SARS-CoV-2 in
symptomatic patients among a low-density population in the
southeastern United States. It is among the largest sequencing
studies that focuses on a suburban and rural community, rather
than a crowded city, like New York City. The SNV distribution
was consistent with continuous evolution or genetic drift of this
new virus through an immunologically naive host population
(Consortium, 2004; Fauver et al., 2020; Lu et al., 2020a).
The first reported SARS-CoV-2 case in NC was a person who
previously traveled to the state of Washington (03-03-2020, NC
State Health Department; GenBank: MT325591). Additional
early cases included persons who became infected while on-
board a cruise ship (03-12-2020, NC State Health Department).
Each of these introduction events was associated with a distinct
clade. More recent cases, and cases in neighboring Virginia,
were associatedwith the cruise case. These data support the hy-
pothesis that the majority of cases in NC originate from persons
traveling within the United States rather than internationally, re-
flecting predominant spread by community transmission within
the United States (Fauver et al., 2020).
SNV analysis documents the presence of a presumed high-
pathogenicity variant D614G in 57% of the cases (Becerra-
Flores and Cardozo, 2020; Ceraolo and Giorgi, 2020; Eaaswar-
khanth et al., 2020). It is clear that this variant signifies spread
within Europe and the continental United States. Within the lim-
itations presented by measuring viral loads within samples
collected at unknown times past infection and with presumably
differing clinical sampling efficiency, patients with the D614G
SNV presented with higher SARS-CoV-2 genome loads. The as-
sociation of the D614G SNV with specific clinical presentations,
distinct biological properties, and high peak titers seems
increasingly likely (Zhang et al., 2020). While this article was un-
der review, a large number of studies cemented the importance
of the D614G SNV and its biological and clinical properties.
Figure 3. Detailed Mapping of the Variant
29745delta14
(A) Reads mapped to the reference sequence
NC_045512.
(B) The same reads mapped to an artificial target
sequence with the 29745delta14. Blue indicates
forward and red reverse reads (all reads are single
reads). Red boxes and black bars indicate mis-
matches at below 20%of reads (red) or above 20%
of reads (black). In this alignment, duplicate map-
ping reads were removed to guard against PCR
amplification bias. Genome positions are shown on
top (note that after nucleotide 29,745, genome
positions are out of sync due to the deletion).
Note that this region is within the CoV 30 stem-loop
II-like motif (s2m), annotated in NC_045512 as
a prediction based on profile:Rfam-release-
14.1:RF00164,Infernal:1.1.2.
(C) Predominant Mfold prediction of the 30 end of
NC_045512 with deletion bases indicated in yel-
low.
(D) Predominant Mfold prediction of the 30 end of
NC_045512 delta14.
(E) Sequence alignment of 30 UTR deletion mutants
with other representative SARS-CoV-2 isolates.
(F) Sanger sequencing confirmation of the 30 UTR
deletion mutant UNC_200313_2020/2020.
(G) Sanger sequencing confirmation wild-type
sequence for isolate UNC_200399_2020/2020.
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containing viruses or pseudotyped particles (Li et al., 2020b).
Cao et al. reported on a clustering of genomes that harbor a
D614G mutation in the S gene (Cao et al., 2020). Their analysis
of 489 genomes derived from 32 countries reveals that genomes
in clades A2 and A2a harboring the D614G mutation originate
mainly from European and several South American countries,
different from clade B, which contains genomes from mainland
China. This observation is mirrored in the extensive analysis by
Korber et al. (2020), which was published while this article was
under review. The D614Gmutation dominates over the initial hu-
man strain defined by the SARS-CoV-2/human/CHN/Wuhan-01/
2019 isolate. They observed on average higher genome copy
numbers for the D614G isolate, similar to this study, but could
not make a conclusive association with clinical outcomes.
Several other mutations reportedly accompany the D614G mu-
tation on the S gene and include C214T, C3037T, and the
C14408T mutations, and together, these form the globally domi-Cenant strain of SARS-CoV-2 (Isabel et al.,
2020; Korber et al., 2020). The clade G
strain of SARS-CoV-2 was reported in
Italy as early as February 2020 (Bartolini
et al., 2020; Stefanelli et al., 2020; Ze-
hender et al., 2020). Studies of Russian
isolates also have identified D614G, as
well as additional mutations (Kozlovskaya
et al., 2020). These findings are consistent
with ours, as most of the genomes con-
taining the D614G mutation also carry
additional mutations defining the G clade.Of the 87 sequences that have the D614G mutation, 69 have the
C214T mutation, 15 have the C3037T mutation, and 48 have the
C14408T mutation. Given the increasing abundance of D614G
SNVs, further research into its role in pathogenicity and clinical
outcomes is warranted.
Four samples had the same 14-nt deletion in the 30 UTR, and
no samples had deletions within the coding region. This deletion
is 71 nt away from the stop codon of ORF10 (N protein) and elim-
inates a predicted stem-loop structure. An analogous bulged
stem loop at approximately the same location (right after the
stop codon) is important for the replication of mouse hepatitis vi-
rus. In bovine CoVs, an analogous RNA structure attenuates viral
replication (Williams et al., 1999; Z€ust et al., 2008). There seems
to be partial overlap between the bulged stem loop and the pseu-
doknot, suggesting that these two structures are mutually exclu-
sive and may serve as a switch to regulate the ratio of full-length
RNA and defective RNA (Goebel et al., 2004). These two struc-
tures are also present in SARS-CoV. These isolates representll Reports 33, 108352, November 3, 2020 7
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OPEN ACCESSfull-length genomes from symptomatic patients rather than
disjointed RNA fragments recovered after clinical disease had
subsided; thus, we speculate that these deletion mutants are
replication competent yet have an altered ratio of full-length
genomic and defective interfering RNAs. The biological pheno-
types of these and other recent SNVs remain to be established
in future studies.
There are limitations to our approach. These are similar to
other NGS-based phylogeny reconstructions. Sampling was
neither randomized nor exhaustive. At this point, we cannot
exclude the presence of a founder effect and a disproportional
impact of particular populations and situations on this dataset.
The unknown group of samples included individuals who were
not asymptomatic in a broader sense of being negative for any
respiratory symptoms. In the current time of limited personal
protective equipment, limited sample kits, and limited testing ca-
pacity, it would not have been ethical to divert these resources
for random population-wide sequencing. As properly random-
ized cohort studies become available in the future, the SARS-
CoV-2 phylogeny will become more representative of SARS
biology and less influenced by sample bias.
Some SNVs may be the result of technical bias. For instance,
the 50 end awaits individual confirmation by RACE; the 30 end
likewise requires RACE for genome finishing. The Nextstrain
database (Hadfield et al., 2018) suggests that positions 18,529,
29,849, 29,851, and 29,853 may be subject to PCR or
sequencing bias. Lastly, targeted sequencing relies on amplifi-
cation or hybridization capture. Unless the amplicon PCR
primers or capture baits are completely removed, a portion of
reads will reflect the sequence that these primers/baits were
derived from rather than the sample. Most protocols rely on bio-
informatic primer pruning alone. AmpliSeq, in addition to bio-
informatic removal, enzymatically digests the targeting primers
before library construction. Therefore, the sequences and
SNVs reported here could exclusively be attributed to the partic-
ular clinical sequence.
This particular sequencing experiment was not designed to
identify minority variants, as current whole-genome amplification
primer sets do not include unique molecular identifiers (UMIs).
UMIs, sometimes called ‘‘primer IDs,’’ have been pioneered for
sequencing small regions of the HIV genome (Jabara et al.,
2011), and could likewise be applied to SARS-CoV-2.
This study confirmed the sensitivity of current NATs concern-
ing the specific SARS-CoV-2 strains circulating in the region
(and the United States). None of the UNC isolates had mutations
in the CDC primer binding sites (Lu et al., 2020c). Three Euro-
pean isolates (MT358642, MT358639, and MT318827) had a
GGG>AAC polymorphism in the 50 terminal end of the forward
CDC N3 (50-GGGGAACTTCTCCTGCTAGAAT), which is a CoV
consensus primer. Another European isolate (MT35638) had a
G>T at 12,725, which is within the nCoV_IP2 forward primer.
One European and one Chinese isolate (MT358638 and
MT226610) each had a SNV in nCoV_IP2 reverse primer at po-
sitions 12,818 and 12,814. As more and more viral genome se-
quences are generated, more and more SNVs will be recorded,
including SNV in qPCR primer and probe binding sites.
Currently (May 9, 2020), 2.7% and 0.68% of sequences in GI-
SAID contain SNVs in the CDC primer pairs N1 and N2, respec-8 Cell Reports 33, 108352, November 3, 2020tively. These data should be interpreted with caution, since at
this point, little standardization exists as to the quality of SNVs
reported, and it is unclear how much a given SNV in one of
the primer binding sites affects assay performance. Not all mu-
tations in a primer binding site result in catastrophic failure or
significant loss of sensitivity (Hilscher et al., 2005), which is
defined as the sum of all steps in the assay pipeline, including,
e.g., proper sample collection of the patient. Periodic retesting
of positive and negative samples by whole-genome NGS repre-
sents an option to increase sensitivity and specificity and detect
any variants emerging in the populations, which may escape
detection by NAT.
Testing by sequencing represents an interesting alternative to
NAT in the case of CoVs, which are present at very high genome
copy numbers during days of active shedding (Wölfel et al.,
2020; Yu et al., 2020). Testing by SARS-CoV-2 targeted
sequencing had perfect specificity but lower sensitivity than
qPCR (Sellers et al., 2020). Sequence coverage correlated with
viral load. The lower sensitivity was expected, as real-time
qPCR amplicons can be placed anywhere on the target genome
and optimized for sensitivity (Corman et al., 2020); shorter ampli-
cons (<100 bp)maximize sensitivity as compared to larger ampli-
cons (>200 bp) (Hilscher et al., 2005; Lock et al., 2010). By
contrast, NGS represents a compromise, as the entire viral
genome has to be covered with primers that are part of a com-
mon pool. Primer design is governed by compatibility under a
single set of conditions (annealing temperature) as much as by
individual efficiency. The ARTIC network protocol uses n = 96
larger amplicons (https://artic.network/ncov-2019). By compari-
son, the AmpliSeq protocol deployed here uses n = 237 ampli-
cons of size 204 ± 29 (mean ± SD) (i.e., twice as many and sub-
stantially shorter amplicons with expected higher sensitivity). In
sum, testing by sequencing represents a suitable, albeit expen-
sive, tool for COVID-19 diagnosis.
Approximately half of the specimens not clinically tested for
SARS-CoV-2 had a positive result by sequencing. This was not
surprising, as to this day, testing capabilities are limited and
probable cases are triaged based on clinical and public health in-
dications. These unknown cases were not asymptomatic but
represent patients with a clinically indicated need for upper res-
piratory sampling. Finding additional SARS-CoV-2 cases in this
population suggests that case counts based on NAT represent
a lower estimate of SARS-CoV-2 prevalence. It may also suggest
that the current triage criteria for SARS-CoV-2 testing are too
limited to understand spread of this virus. In sum, this study un-
derscores the sensitivity and accuracy of current NAT assays
and demonstrates the utility of testing by sequencing. It contrib-
utes to the worldwide effort to understand and combat the
COVID-19 pandemic by providing an extensive set of full-length
SARS-CoV-2 genomes from a non-urban setting.STAR+METHODS
Detailed methods are provided in the online version of this paper
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Bacterial and Virus Strains
2019-nCoV N/A N/A
Chemicals, Peptides, and Recombinant Proteins
rDNase Macherey-Nagel 740963
DTT, No-Weigh Fisher Scientific A39255
T4 Gene 32 Protein New England Biolabs M0300L
RNase H Life Technologies AM2293
1X GIBCO PBS Life Technologies 14190-144
5.1 SYBR Select Master Mix Thermo Fisher 4472920
Ion AmpliSeq Chef Reagents DL8 Thermo Fisher A29025
Ion AmpliSeq Chef Solutions DL8 Thermo Fisher A29026
Ion AmpliSeq Chef Supplies DL8 Thermo Fisher A29027
Ion S5 Chef Supplies Thermo Fisher A27755
Ion S5 Chef Solutions Thermo Fisher A27754
Ion 510 and Ion 520 and Ion 530 Chef Reagents Thermo Fisher A34018
Ion S5 Sequencing Solutions Thermo Fisher A27767
Ion S5 Sequencing Reagents Thermo Fisher A27768
Critical Commercial Assays
MagNA Pure Compact Nucleic Acid
Isolation Kit – Large Volume
Roche 4729757001
NucleoSpin Virus Macherey-Nagel 740983.5
High-Capacity cDNA Reverse Transcription Kit Life Technologies 4374967
Deposited Data
R code for analysis This paper http://bitbucket.org/account/signin/
?next=/dittmerlab/vironomicscovidunc.git
SARS-CoV-2 sequence reads This paper PRJNA639551
SARS-CoV-2 sequence reads This paper PRJNA633048
Oligonucleotides
Primer 2019-nCoV_N1-F

















R Version 3.6 The R Project for
Statistical Computing
https://www.r-project.org
CLC Genomics Workbench Version 11 QIAGEN https://digitalinsights.qiagen.com
Geneious Prime 2019 Version 2.3 Geneious https://www.geneious.com
BBduk Version 37.36 Joint Genome Institute https://jgi.doe.gov
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REAGENT or RESOURCE SOURCE IDENTIFIER
MEGA X Molecular Evolutionary
Genetics Analysis
https://www.megasoftware.net/home
Freedom Evoware Tecan EVOWARE20
Other
IonCode 0101-0132 in 96 Well PCR Plates Thermo Fisher A29028
0.2 ml tubes 8-tube strip with caps USA Scientific 1402-4700
0.2 ml tubes 12-tube strip with caps USA Scientific 1402-2400
0.2 ml 96 well PCR plate USA Scientific 1402-9300
Thermal Cycler ThermoFisher 4375786
5.4. LightCycler 480 Sealing Foil Roche 4729757001
Lightcycler 480 SW 1.5 Roche 5015278001
Lightcylcer 480 384-well qPCR plates Roche 4729749001





Further information and requests for resources and reagents should be directed to and will be fulfilled by Melissa Miller (Melissa.
miller@unchealth.unc.edu), and Dirk Dittmer (dirkdittmer@me.com).
Materials Availability
Complete SARS-CoV-2 genomes meeting the confidence criteria elaborated on below were uploaded to GenBank and contributed
to GISAID (GISAID, 2020). Other sequences, including index cases in the state of North Carolina, as deposited by the State Health
Department were provided by GISAID. Other materials are listed in the Key Resources Table of this manuscript.
Data and Code Availability
All sequence mapping algorithms and codes are publicly accessible, listed in detail below, or available using the CLC Genomics
Workbench V 2.0 (QIAGEN Inc.). R code that was used for data analysis is located on an accessible bit bucket folder https://
bitbucket.org/dittmerlab/unc_covid_ampliseq/. SARS-CoV-2 RNAseq positive control sequence reads (Supplemental Figures
S1A-S1D) were uploaded under Bioproject PRJNA639551, PRJNA633048. All custom coding is available upon request through
the Lead Contact information above.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
This study used remnant samples of universal transport media (UTM) from provider-collected deep nasopharyngeal (NP) swabs
(https://www.cdc.gov/coronavirus/2019-ncov/lab/guidelines-clinical-specimens.html) after their clinical purpose had been
completed. The SARS-CoV-2 status of each sample was determined by a clinical NAT approved under EUA at The University of North
Carolina at Chapel Hill Medical Center (UNCMC) McLendon Clinical laboratories. None of the samples carried any identifiers other
than the date of testing. Hence, this research was considered part of the QA/QC effort to support clinical testing and classified as
non-human subject research by local IRB.
METHOD DETAILS
RNA isolation
250 mL of virus transport medium (VTM) from flocked NP swabs were adjusted to 1.0 mL with 0.1% Triton X-100 (proteomics grade,
VWR: 97063-864) diluted in 1X phosphate-buffered saline (PBS, Life Technologies, Catalog # 14190-144). Samples were incubated
at room temperature for 30 minutes in a 2.0 mL screw cap tube (Genesee # 21-265), vortexing every 5minutes for 15 s pulses. 200 mL
of the permeabilized sample was then processed using the Machery-Nagel NucleoSpin Virus kit (Macherey-Nagel, Catalog #
740983.50 and 740983.250). Carrier RNA (poly-A salt) was added to the mixture to a final concentration of 9 ng/mL. DNase digestion
was performed post-column binding (Macherey-Nagel, Catalog #740963) at room temperature for 5 minutes at a final concentration
of 40 ng/mL. RNA was eluted from the column using 60 mL of RNase-free water pre-heated to 70 C. For each processing batch, a
negative reagent control and a negative cell pellet control was used. The reagent control consisted of 250 mL of 1X PBS insteadCell Reports 33, 108352, November 3, 2020 e2
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OPEN ACCESSof 250 mL of the sample in UTM. The cell pellet controls used were stored at 80 C before the emergence of SARS-CoV-2. The total
number of cells used per negative control was 106 and were treated identically and concurrently to the UTM and reagent control pro-
cessed samples. The 60 mL of eluted RNA was processed for sequencing and viral load as described below.
Real-time qPCR
Relative viral genome copy number was ascertained by real-time qPCR using primers and procedures established by the CDC (Lu
et al., 2020c). 30 mL input RNA was subjected to hexamer-primed reverse transcription. 9 ml cDNA was used for qPCR containing
125 nM for each primer and SYBR green as the method of detection on a Roche LC480II Lightcycler and crossing point (CP) values
determined by an automated threshold method.
Next-Generation Sequencing
As a positive control, we used Genomic RNA from SARS-Related Coronavirus 2, Isolate USA-WA1/2020, as provided by BEI/ATCC.
This reagent was deposited by the Centers for Disease Control and Prevention and obtained through BEI Resources, NIAID, NIH: NR-
52285. All samples were sequenced using random hexamer/dT priming as provided by the Thermo SARS-CoV-2 AmpliSeq kit ac-
cording tomanufacturer’s recommendations on an IonTorrent Chef and IonTorrent S5 sequencer. The amplicons are tightly tiled and
overlapping. Amplicon sizes ranged between 68 and 232 nucleotides after trimming of low-quality sequences and all primer se-
quences (125-275 before trimming).
Cloning and Sanger sequencing of 50UTR stem-loop deletion PCR amplification
Multiple primer pairs were designed on Benchling (https://www.benchling.com) that flanked the deletion in the 30UTR at position
29321-29845 of the SARS-CoV-2 reference genome (NC_045512): Primer 1 forward: AGGGAGGACTTGAAAGAGCC, reverse:
GGGCTCTTCCATATAGGCAG; Primer 2 forward: CTCGTAACTACATAGCACAAGTAGTG, reverse: ATCACATGGGGATAGCAC-
TACTA; Primer 3 forward: CGTTTTCGCTTTTCCGTT, reverse: TCACATGGGGATAGCACTACT; Primer 4 forward: GCAATCTTTAAT-
CAGTGTAACATTAG, reverse: GCTCTTCCATATAGGCAGCTC; Primer 5 forward: ATTGGCATGGAAGTCACACC, reverse:
GCTCTTCCATATAGGCAGCTC. Next 10mL of the extracted cDNA was amplified in a 50mL PCR reaction. Reaction mixtures con-
tained 25mL of 2X GoTaq Promega Master mix (#M712C), 2.5mL primers (0.5mM), and brought to volume with nuclease-free water.
The PCRwas performedwith an initial denaturation step a 95C for 2minutes, the PCR cycled at 95C for 30 s, 56C for 1minute, and
73C for 1 minute for 40 cycles, followed by a final extension at 73C for 10 minutes and a 4C hold. The annealing temperature was
derived from the primer pair melting temperatures. Primer PCR products were visualized on a 1.5% agarose gels and PCR bands
were gel purified using the QIAGEN Gel Purification Kit (QIAGEN Inc.). Purified DNA was eluted in 30mL nuclease-free water and
PCR products were cloned using TOPO-TA for sequencing, transformed in the supplied One Shot Top 10 E. coli competent cells
(Invitrogen, #K457540). Multiple clones from multiple PCR reactions for each case were confirmed by Sanger Sequencing (Genewiz
Inc.). Sequences were aligned to the deleted and wild-type consensus sequence on CLC Genomics Workbench v.20 (QIAGEN Inc.).
Bioinformatic analysis
Following primer trimming according to themanufacturer’s recommendations, additional, custom steps were added. Specifically, all
sequences were quality trimmed using the bbduk script (arguments: qtrim = rl trimq = 20 maq = 20 minlen = 40 tpe tbo) from bbmap
version 37.36. Each trimmed sequence was analyzed using CLC Genomics Workbench version 11.0. The trimmed reads were map-
ped to the SARS-COV-2 reference sequence isolate SARS-CoV-2/human/CHN/Wuhan-01/2019 (NCBI Accession: NC_045512).
From eachmapping, the followingwas collected: a consensus sequence, sequence variants, andmapping coverage. The consensus
sequence was extracted from the mapping by quality voting. Regions at or below a coverage threshold of 3 were considered low
coverage and N’s were inserted for ambiguity.
SNVwere called using theCLC bio algorithm (QIAGEN Inc.) for human genome SNV calling. The threshold for reporting was set at >
90% frequency and a minimum coverage of 10-fold with balanced forward and reverse reads for all SNV.
Targeted regions were determined via Thermo SARS-CoV-2 designed BED file and sequences with 1x coverage across more than
99% of the 237 SARS-COV-2 amplicons were considered complete sequences. Any sequences with 1x coverage between 5% and
99% were considered partial genomes. Partial genomes are included in the variant calling analysis but were not submitted to Gen-
Bank or GISAID.
All consensus sequences derived from this study were manually curated to revert poly-nucleotide-tract mutations to the reference
sequence.
Phylogenetic reconstruction
Full-length, viral genome consensus sequences were aligned using MAFFT (Katoh and Standley, 2013) with a PAM200 / k = 2
scoring matrix, gap open penalty of 1.53 and offset value of 0.123 as implemented in Genious (Genious Ltd) using n = 92 se-
quences. A neighbor-joining tree was constructed using Genious Tree Builder (Genious Ltd) with bat coronavirus strain RaTG13
(GenBank: MN996532) as an outgroup. The number of bootstrap replicates was 1,000 with a support threshold of > 50%. S protein
sequences were analyzed using MEGA X version 10.1.7 (Kumar et al., 2018). Specifically, evolutionary history was inferred using
the Neighbor-Joining method (Saitou and Nei, 1987). The optimal tree with the sum of branch length = 0.6557 is shown. The per-e3 Cell Reports 33, 108352, November 3, 2020
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OPEN ACCESScentage of replicate trees in which the associated taxa clustered together in the bootstrap test (800 replicates) are shown next to
the branches. The evolutionary distances were computed using the Maximum Composite Likelihood method (Tamura et al., 2004)
and are in the units of the number of base substitutions per site. The rate variation among sites was modeled with a gamma dis-
tribution (shape parameter = 1). This analysis involved 96 nucleotide sequences. Codon positions included were
1st+2nd+3rd+Noncoding. All positions with less than 95% site coverage were eliminated, i.e., fewer than 5% alignment gaps,
missing data, and ambiguous bases were allowed at any position (partial deletion option). There were 3,822 positions in the final
dataset. Further sequences, including the NC index cases, as deposited by the State Health Department were provided by GISAID
(GISAID, 2020).
QUANTIFICATION AND STATISTICAL ANALYSIS
Further statistical analysis and visualization was conducted using R v 4.0.0. The code is available on bitbucket.Cell Reports 33, 108352, November 3, 2020 e4
